首页> 美国卫生研究院文献>other >Genome Mining of the Marine Actinomycete Streptomyces sp. DUT11 and Discovery of Tunicamycins as Anti-complement Agents
【2h】

Genome Mining of the Marine Actinomycete Streptomyces sp. DUT11 and Discovery of Tunicamycins as Anti-complement Agents

机译:海洋放线菌Streptomyces sp。的基因组挖掘。 DUT11和衣霉素作为抗补体剂的发现

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Marine actinobacteria are potential producers of various secondary metabolites with diverse bioactivities. Among various bioactive compounds, anti-complement agents have received great interest for drug discovery to treat numerous diseases caused by inappropriate activation of the human complement system. However, marine streptomycetes producing anti-complement agents are still poorly explored. In this study, a marine-derived strain Streptomyces sp. DUT11 showing superior anti-complement activity was focused, and its genome sequence was analyzed. Gene clusters showing high similarities to that of tunicamycin and nonactin were identified, and their corresponding metabolites were also detected. Subsequently, tunicamycin I, V, and VII were isolated from Streptomyces sp. DUT11. Anti-complement assay showed that tunicamycin I, V, VII inhibited complement activation through the classic pathway, whereas no anti-complement activity of nonactin was detected. This is the first time that tunicamycins are reported to have such activity. In addition, genome analysis indicates that Streptomyces sp. DUT11 has the potential to produce novel lassopeptides and lantibiotics. These results suggest that marine Streptomyces are rich sources of anti-complement agents for drug discovery.
机译:海洋放线菌是具有多种生物活性的各种次级代谢产物的潜在生产者。在各种生物活性化合物中,抗补体剂已引起人们对药物开发的极大兴趣,这种药物可用于治疗由于人补体系统的不适当激活而引起的多种疾病。然而,生产抗补体剂的海洋链霉菌仍然很少被探索。在这项研究中,海洋衍生的菌株链霉菌。关注显示出优异的抗补体活性的DUT11,并分析其基因组序列。鉴定出与衣霉素和非肌动蛋白具有高度相似性的基因簇,并且还检测了它们的相应代谢产物。随后,从链霉菌属物种中分离了衣霉素I,V和VII。 DUT11。抗补体测定显示衣霉素I,V,VII通过经典途径抑制补体激活,而未检测到非肌动蛋白的抗补体活性。这是首次报道衣霉素具有这种活性。另外,基因组分析表明链霉菌sp。 DUT11具有产生新型脂肽和羊毛硫抗生素的潜力。这些结果表明,海洋链霉菌是用于药物发现的抗补体剂的丰富来源。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号